CDK-9
Showing 1 - 25 of 5,830
Learn About Use and Effects of CDK4/6 Inhibitors in Canadian
Active, not recruiting
- Breast Cancer
-
Kirkland, Quebec, CanadaPfizer Canada
Mar 5, 2023
Cutaneous T-cell Lymphoma (CTCL) Trial in United Kingdom (CDK-003)
Recruiting
- Cutaneous T-cell Lymphoma (CTCL)
- CDK-003
-
Birmingham, United Kingdom
- +3 more
Apr 22, 2022
Advanced Solid Tumor Trial in United Kingdom, United States (CDK-002)
Active, not recruiting
- Advanced Solid Tumor
- CDK-002
-
Scottsdale, Arizona
- +7 more
Sep 27, 2022
Leukemia, Myelodysplastic Syndrome(MDS) Trial in Duarte, Houston (fadraciclib)
Recruiting
- Leukemia
- Myelodysplastic Syndrome(MDS)
-
Duarte, California
- +1 more
Apr 1, 2022
Prostate Cancer Trial in Canada (Palbociclib)
Active, not recruiting
- Prostate Cancer
-
Halifax, Nova Scotia, Canada
- +6 more
Jan 28, 2022
Breast Cancer Trial in Australia, Canada, New Zealand (Ipatasertib, Fulvestrant, Placebo)
Recruiting
- Breast Cancer
- Ipatasertib
- +2 more
-
Bowral, New South Wales, Australia
- +37 more
Aug 8, 2022
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in
Completed
- Relapsed or Refractory Haematological Malignancies Including
- +10 more
-
Aachen, Germany
- +11 more
Oct 21, 2021
Metastatic NSCLC, NSCLC, Lung Cancer Trial in United States (Trilaciclib, Placebo, Docetaxel)
Terminated
- Metastatic Non-Small Cell Lung Cancer
- +2 more
- Trilaciclib
- +2 more
-
Phoenix, Arizona
- +11 more
Feb 11, 2022
Mantle Cell Lymphoma Trial in France, Germany (Abemaciclib)
Active, not recruiting
- Mantle Cell Lymphoma
-
Lille, France
- +6 more
Apr 6, 2022
Advanced Cancer Trial in Santa Monica, Boston, San Antonio (LY2835219, Fulvestrant)
Active, not recruiting
- Advanced Cancer
-
Santa Monica, California
- +2 more
Oct 4, 2021
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer Trial in United Kingdom (Ipatasertib 300mg, Fulvestrant
Not yet recruiting
- Metastatic Breast Cancer
- +2 more
- Ipatasertib 300mg
- +3 more
-
Cambridge, Cambridgeshire, United Kingdom
- +19 more
Jun 3, 2021
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer Trial in Canada (Endocrine therapy may include one of the following
Active, not recruiting
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
- Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
-
Calgary, Alberta, Canada
- +24 more
Sep 12, 2022
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Breast Tumors Trial in Worldwide (Abemaciclib, Fulvestrant, Placebo)
Active, not recruiting
- Breast Neoplasms
- Abemaciclib
- +2 more
-
Fayetteville, Arkansas
- +141 more
Nov 15, 2022
Breast Cancer Trial in Worldwide (Abemaciclib, Anastrozole, Letrozole)
Metastatic Breast Cancer, Breast Cancer Stage IV Trial in São Paulo
Recruiting
- Metastatic Breast Cancer
- Breast Cancer Stage IV
-
São Paulo, SP, BrazilHcor
Sep 26, 2022
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
Metastatic Breast Cancer Trial in United States (Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane
Recruiting
- Metastatic Breast Cancer
- Enobosarm & Abemaciclib Combo
- non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
-
Chandler, Arizona
- +29 more
Feb 1, 2023
ER-Positive HER2-Negative Breast Cancer Trial in Worldwide (AZD9833, AZD9833 Placebo, Anastrozole)
Recruiting
- ER-Positive HER2-Negative Breast Cancer
- AZD9833
- +8 more
-
Phoenix, Arizona
- +215 more
Aug 4, 2022
Tumors Trial in Seoul (abemaciclib+paclitaxel)
Active, not recruiting
- Tumors
-
Seoul, Korea, Republic ofSeverance Hospital
May 30, 2022
